The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti progra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kooshkaki, Omid, Derakhshani, Afshin, Safarpour, Hossein, Najafi, Souzan, Vahedi, Parviz, Brunetti, Oronzo, Torabi, Mitra, Lotfinejad, Parisa, Paradiso, Angelo Virgilio, Racanelli, Vito, Silvestris, Nicola, Baradaran, Behzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404077/
https://www.ncbi.nlm.nih.gov/pubmed/32708748
http://dx.doi.org/10.3390/ijms21145034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404077/
https://www.ncbi.nlm.nih.gov/pubmed/32708748
http://dx.doi.org/10.3390/ijms21145034

Ejemplares similares